These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11512520)

  • 1. Lamivudine resistance in hepatitis B: mechanisms and clinical implications.
    Fischer KP; Gutfreund KS; Tyrrell DL
    Drug Resist Updat; 2001 Apr; 4(2):118-28. PubMed ID: 11512520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
    Kennedy PT; Phillips N; Chandrasekhar J; Jacobs R; Jacobs M; Dusheiko G
    Liver Int; 2008 May; 28(5):699-704. PubMed ID: 18433396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
    Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
    Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.